Cognito Therapeutics
Medical Devices, 1218 Ave Ste 200, Cambridge, Massachusetts, 02138, United States, 11-50 Employees
Phone Number: 85********
Who is COGNITO THERAPEUTICS
Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical ...
Read More
-
Headquarters: 1218 Massachusetts Ave Ste 200, Cambridge, Massachusetts, 02138, United States
-
Date Founded: 2016
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Medical Devices
SIC Code: 8731
|
NAICS Code: 54 |
Show More
Does something look wrong? Fix it. | View contact records from COGNITO THERAPEUTICS
Cognito Therapeutics Org Chart and Mapping
Email
Phone
Similar Companies to Cognito Therapeutics
Cognoa
-
51-200
-
$ 100 Million to 250 Million
SetPoint Medical
-
51-200
-
$ 10 Million to 25 Million
Sinaptica Therapeutics
-
1-10
-
$ 1 Billion and Over
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Cognito Therapeutics
Answer: Cognito Therapeutics's headquarters are located at 1218 Ave Ste 200, Cambridge, Massachusetts, 02138, United States
Answer: Cognito Therapeutics's phone number is 85********
Answer: Cognito Therapeutics's official website is https://cognitotx.com
Answer: Cognito Therapeutics's revenue is $1 Million to $5 Million
Answer: Cognito Therapeutics's SIC: 8731
Answer: Cognito Therapeutics's NAICS: 54
Answer: Cognito Therapeutics has 11-50 employees
Answer: Cognito Therapeutics is in Medical Devices
Answer: Cognito Therapeutics top competitors include: Cognoa , SetPoint Medical , Sinaptica Therapeutics
Answer: Cognito Therapeutics contact info: Phone number: 85******** Website: https://cognitotx.com
Answer: Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimers disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimers disease and expects to start pivotal studies in 2022. The companys technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month